Thrombotic thrombocytopenic purpura overview

Jump to navigation Jump to search

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura overview

CDC on Thrombotic thrombocytopenic purpura overview

Thrombotic thrombocytopenic purpura overview in the news

Blogs on Thrombotic thrombocytopenic purpura overview

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Thrombotic thrombocytopenic purpura (TTP or Moschcowitz disease) is a rare disorder of the blood-coagulation system, causing multiple blood clots to form in blood vessels around the body.[1] Most cases of TTP arise from deficiency or inhibition of the enzyme ADAMTS13, which is responsible for cleaving large multimers of von Willebrand factor.[2] This leads to hemolysis and end-organ damage, and may require plasmapheresis therapy.

References

  1. "MedlinePlus: Thrombotic thrombocytopenic purpura", MedlinePlus Medical Encyclopedia, 2007, webpage: NLM-552.
  2. Moake JL (2004). "von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura". Semin. Hematol. 41 (1): 4–14. PMID 14727254.

Template:WH Template:WS